Hypothesis: Proteasome activity assay

Query: You are a professional biomedical researcher, having experience in early-stage drug discovery and validation in vitro. Your task is to evaluate cell culture assays that would be used to evaluate drugs to treat Charcot-Marie-Tooth Disease.
        Given the following assay, do a comprehensive literature review to evaluate if this assay would be useful for testing therapeutics for Charcot-Marie-Tooth Disease. Search relevant literature across
        biomedical, clinical, and biochemical literature about the disease or therapeutic landscape. Don't look up specific drugs, but any relevant scientific information that may inform assay development.Strategy: Proteasome activity assay
Reasoning: Excess misfolded PMP22 overloads proteasomal degradation; cleavage of the fluorogenic substrate Suc-LLVY-AMC in Schwann cell lysates provides a direct measure of 20S proteasome activity and its pharmacological enhancement (Benoy et al. 2015; Finkbeiner 2020).Provide your response in the following format, like an evaluation for a scientific proposal:
        Assay Overview: Explain the assay idea, including the following key points: which aspect of the disease pathogenesis does the assay model, what measurements will be taken from the assay and how they will be taken, which cells or other biological material are used in the assay.
        Biomedical Evidence: Make a compelling argument for how the aspect of the disease represented in the assay is central to the pathogenesis of the disease. Make sure to consider both the biomedical and clinical literature.
        Previous Use: Explain how this assay has previously been used for drug discovery (if this has been done). Explain any key scientific discoveries which have been made using this assay.
        Overall Evaluation: Strengths and weaknesses of this assay for testing therapeutics for Charcot-Marie-Tooth Disease.

Assay Overview:
This assay employs measurement of proteasome activity using the chymotrypsin-like cleavage of the fluorogenic substrate Suc-LLVY-AMC in lysates derived from Schwann cells, which are key targets in Charcot-Marie-Tooth Disease (CMT). The central idea is to quantify the degradation capacity of the 20S proteasome complex, as PMP22 overexpression in CMT leads to its misfolding and aggregation, ultimately overloading the ubiquitin-proteasome system (UPS). The assay directly measures fluorescent AMC release upon substrate cleavage, serving as a quantitative indicator of proteasomal function. Schwann cell lysates from relevant in vitro models (or animal models such as the C22 mouse model) provide the biological material, ensuring that the readout reflects cellular PQC (protein quality control) dynamics associated with PMP22-induced proteotoxic stress (chittoor2013biochemicalcharacterizationof pages 1-2, chittoor2013biochemicalcharacterizationof pages 3-4).

Biomedical Evidence:
Pathogenesis in CMT, particularly in CMT1A, is tightly linked to an aberrant increase in PMP22 protein levels, leading to its misfolding and aggregation within Schwann cells. The accumulation of misfolded PMP22 disrupts protein trafficking and overloads the proteasome, compromising the cell’s ability to maintain proteostasis. This is central to disease pathogenesis, as proteasomal dysfunction in Schwann cells contributes directly to demyelination and the progression of neuropathy. Multiple studies have demonstrated that reduced proteasome activity, evidenced by decreased cleavage of specific fluorogenic substrates such as Suc-LLVY-AMC, is associated with increased levels of ubiquitinated proteins and misfolded PMP22 aggregates in both CMT models and patient samples (chittoor2013biochemicalcharacterizationof pages 10-12, marinko2020directrelationshipbetween pages 1-2). Moreover, the clinical observations of demyelination in CMT patients further emphasize that dysfunction in proteostasis is not only biologically relevant but also clinically significant (lee2012proteinmisfoldingand pages 1-2, patzko2011updateoncharcotmarietooth pages 6-7).

Previous Use:
Proteasome activity assays using substrates like Suc-LLVY-AMC have been previously applied to study the progression of proteostatic deficits in CMT models. In these studies, particularly using the C22 transgenic mouse model, researchers observed an age-dependent reduction in proteasomal activity, correlating with increased misfolded PMP22 aggregates and ubiquitin-positive inclusions in Schwann cells (chittoor2013biochemicalcharacterizationof pages 6-7, chittoor2013biochemicalcharacterizationof pages 4-6). This approach has been a cornerstone for establishing the link between proteasomal overload and Schwann cell pathology in CMT, thereby validating the assay as a functional readout for therapeutic screening. Its successful use has provided insights into the biochemical pathways by which PMP22 misfolding induces cellular stress and contributes to demyelination.

Overall Evaluation:
Strengths of this assay include its direct measurement of a key biochemical process implicated in CMT pathogenesis. As proteasome dysfunction is a core component of the cellular stress response induced by misfolded PMP22, the assay serves as a robust surrogate marker for testing drugs aimed at enhancing proteasomal capacity or reducing proteotoxic stress. Its quantitative nature and the ability to use primary or immortalized Schwann cell lines also make it amenable to high-throughput formats relevant for early-stage drug discovery (chittoor2013biochemicalcharacterizationof pages 1-2, lee2012proteinmisfoldingand pages 3-4).

However, there are inherent weaknesses to consider. The assay focuses on one aspect of the complex pathology in CMT, capturing only the proteasomal response to misfolded proteins. It may not fully account for other compensatory or parallel degradation systems, such as autophagy, which also modulate proteostasis in Schwann cells (chittoor2013biochemicalcharacterizationof pages 6-7, bai2022treatmentwithifb088 pages 12-14). Moreover, while the biochemical readout is valuable, correlating these findings with functional outcomes such as improved myelination or nerve conduction in vivo may require additional complementary assays. Thus, while this proteasome activity assay is a critical tool for evaluating the pharmacological enhancement of protein quality control mechanisms, it should be integrated within a broader panel of assays to fully capture the therapeutic potential for CMT (patzko2011updateoncharcotmarietooth pages 6-7).

In summary, the proteasome activity assay using Suc-LLVY-AMC in Schwann cell lysates is both scientifically justified and experimentally validated for modeling a critical aspect of CMT pathogenesis and provides a practical platform for early-stage drug screening endeavors.

References:
1. (chittoor2013biochemicalcharacterizationof pages 1-2): Vinita G. Chittoor, Lee Sooyeon, Sunitha Rangaraju, Jessica R. Nicks, Jordan T. Schmidt, Irina Madorsky, Diana C. Narvaez, and Lucia Notterpek. Biochemical characterization of protein quality control mechanisms during disease progression in the c22 mouse model of cmt1a. ASN NEURO, Oct 2013. URL: https://doi.org/10.1042/an20130024, doi:10.1042/an20130024. This article has 25 citations and is from a peer-reviewed journal.

2. (chittoor2013biochemicalcharacterizationof pages 10-12): Vinita G. Chittoor, Lee Sooyeon, Sunitha Rangaraju, Jessica R. Nicks, Jordan T. Schmidt, Irina Madorsky, Diana C. Narvaez, and Lucia Notterpek. Biochemical characterization of protein quality control mechanisms during disease progression in the c22 mouse model of cmt1a. ASN NEURO, Oct 2013. URL: https://doi.org/10.1042/an20130024, doi:10.1042/an20130024. This article has 25 citations and is from a peer-reviewed journal.

3. (chittoor2013biochemicalcharacterizationof pages 3-4): Vinita G. Chittoor, Lee Sooyeon, Sunitha Rangaraju, Jessica R. Nicks, Jordan T. Schmidt, Irina Madorsky, Diana C. Narvaez, and Lucia Notterpek. Biochemical characterization of protein quality control mechanisms during disease progression in the c22 mouse model of cmt1a. ASN NEURO, Oct 2013. URL: https://doi.org/10.1042/an20130024, doi:10.1042/an20130024. This article has 25 citations and is from a peer-reviewed journal.

4. (chittoor2013biochemicalcharacterizationof pages 6-7): Vinita G. Chittoor, Lee Sooyeon, Sunitha Rangaraju, Jessica R. Nicks, Jordan T. Schmidt, Irina Madorsky, Diana C. Narvaez, and Lucia Notterpek. Biochemical characterization of protein quality control mechanisms during disease progression in the c22 mouse model of cmt1a. ASN NEURO, Oct 2013. URL: https://doi.org/10.1042/an20130024, doi:10.1042/an20130024. This article has 25 citations and is from a peer-reviewed journal.

5. (lee2012proteinmisfoldingand pages 1-2): Samuel M. Lee, L. Chin, and Lian Li. Protein misfolding and clearance in demyelinating peripheral neuropathies. Communicative & Integrative Biology, 5:107-110-3331, Jan 2012. URL: https://doi.org/10.4161/cib.18638, doi:10.4161/cib.18638. This article has 26 citations and is from a peer-reviewed journal.

6. (bai2022treatmentwithifb088 pages 12-14): Yunhong Bai, Caroline Treins, Vera G. Volpi, Cristina Scapin, Cinzia Ferri, Rosa Mastrangelo, Thierry Touvier, Francesca Florio, Francesca Bianchi, Ubaldo Del Carro, Frank F. Baas, David Wang, Pierre Miniou, Philippe Guedat, Michael E. Shy, and Maurizio D’Antonio. Treatment with ifb-088 improves neuropathy in cmt1a and cmt1b mice. Molecular Neurobiology, 59:4159-4178, Apr 2022. URL: https://doi.org/10.1007/s12035-022-02838-y, doi:10.1007/s12035-022-02838-y. This article has 30 citations and is from a peer-reviewed journal.

7. (chittoor2013biochemicalcharacterizationof pages 4-6): Vinita G. Chittoor, Lee Sooyeon, Sunitha Rangaraju, Jessica R. Nicks, Jordan T. Schmidt, Irina Madorsky, Diana C. Narvaez, and Lucia Notterpek. Biochemical characterization of protein quality control mechanisms during disease progression in the c22 mouse model of cmt1a. ASN NEURO, Oct 2013. URL: https://doi.org/10.1042/an20130024, doi:10.1042/an20130024. This article has 25 citations and is from a peer-reviewed journal.

8. (lee2012proteinmisfoldingand pages 3-4): Samuel M. Lee, L. Chin, and Lian Li. Protein misfolding and clearance in demyelinating peripheral neuropathies. Communicative & Integrative Biology, 5:107-110-3331, Jan 2012. URL: https://doi.org/10.4161/cib.18638, doi:10.4161/cib.18638. This article has 26 citations and is from a peer-reviewed journal.

9. (marinko2020directrelationshipbetween pages 1-2): Justin T. Marinko, Bruce D. Carter, and Charles R. Sanders. Direct relationship between increased expression and mistrafficking of the charcot–marie–tooth–associated protein pmp22. Journal of Biological Chemistry, 295:11963-11970, Aug 2020. URL: https://doi.org/10.1074/jbc.ac120.014940, doi:10.1074/jbc.ac120.014940. This article has 29 citations and is from a domain leading peer-reviewed journal.

10. (patzko2011updateoncharcotmarietooth pages 6-7): Ágnes Patzkó and Michael E. Shy. Update on charcot-marie-tooth disease. Current Neurology and Neuroscience Reports, 11:78-88, Feb 2011. URL: https://doi.org/10.1007/s11910-010-0158-7, doi:10.1007/s11910-010-0158-7. This article has 215 citations and is from a domain leading peer-reviewed journal.
